Systematic cardio-oncologic screening of patients treated with BRAF and MEK inhibitors
BRAF and MEK inhibitors have significantly improved progression-free and overall survival compared to monotherapy, they carry a high risk of cardiovascular adverse events (CVAEs) because the MAPK pathway is also essential for normal cardiac and vascular physiology. The ESC Guidelines on Cardio-Oncology recommend...